ibrilatazar (ABTL0812)

News alerts, weekly reports and conference planners

Company:

Ability Pharma, SciClone

Drug class:

mTOR inhibitor, PPAR γ agonist, PPAR α agonist

Related drugs:

‹

›

4ms

A Study of ABTL0812 in Pancreatic Cancer (clinicaltrials.gov)

P1/2, N=60, Suspended, Ability Pharmaceuticals SL | Trial completion date: Apr 2024 --> Dec 2024

4 months ago

Trial completion date • Combination therapy • Metastases

gemcitabine • albumin-bound paclitaxel • ibrilatazar (ABTL0812)

8ms

PanC-ASAP: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (clinicaltrials.gov)

P1/2, N=150, Completed, Ability Pharmaceuticals SL | Trial completion date: Sep 2028 --> Jan 2024 | Trial primary completion date: Dec 2024 --> Jan 2024 | Recruiting --> Completed

8 months ago

Trial completion • Trial completion date • Trial primary completion date • Combination therapy • Metastases

5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ibrilatazar (ABTL0812)

12ms

PanC-ASAP: ABTL0812 in Combination With FOLFIRINOX for First-line Treatment of Metastatic Pancreatic Study (clinicaltrials.gov)

P1/2, N=150, Recruiting, Ability Pharmaceuticals SL | Phase classification: P2 --> P1/2

12 months ago

Phase classification • Combination therapy • Metastases

5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • ibrilatazar (ABTL0812)

almost2years

Anticancer effects of ABTL0812, a clinical stage drug inducer of autophagy-mediated cancer cell death, in glioblastoma models. (PubMed, Front Oncol)

Finally, we investigated the combination of ABTL0812 with the standard of care treatments for GBM radiotherapy and temozolomide in an orthotopic model, detecting that ABTL0812 potentiates the efficacy of both treatments and that the strongest effect is obtained with the triple combination of ABTL0812+radiotherapy+temozolomide. Overall, the present study demonstrated the anticancer efficacy of ABTL0812 as single agent and in combination with the GBM standard of care treatments in models of glioblastoma and supports the clinical investigation of ABTL0812 as a potential novel therapy for this aggressive brain tumor type.

almost 2 years ago

Journal

TRIB3 (Tribbles Pseudokinase 3)

temozolomide • ibrilatazar (ABTL0812)

over3years

[VIRTUAL] ABTL0812, a Phase 2 clinical stage pro-autophagy anticancer drug exhibits immunomodulatory effects that modify tumor microenvironment in pancreatic cancer models (AACR 2021)

Overall, these multiple actions could potentially help to transform “cold” non-immunogenic tumors into “hot” immunogenic tumors and contribute to elicit anticancer immunosurveillance. These novel findings support further investigation of ABTL0812 in combination with immunotherapy to treat cancer

over 3 years ago

Clinical • P2 data • Preclinical • PD(L)-1 Biomarker • IO biomarker

KRAS (KRAS proto-oncogene GTPase) • CD8 (cluster of differentiation 8) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • CD4 (CD4 Molecule) • IL10 (Interleukin 10) • HMGB1 (High Mobility Group Box 1) • CALR (Calreticulin) • CXCL5 (Chemokine (C-X-C motif) ligand 5) • GLI2 (GLI Family Zinc Finger 2) • IL1B (Interleukin 1, beta) • TRIB3 (Tribbles Pseudokinase 3)

TP53 mutation • KRAS mutation

ibrilatazar (ABTL0812)

over4years

[VIRTUAL] Phase II of ABTL0812, a pro-autophagic drug, in combination with paclitaxel and carboplatin (P/C) as first-line treatment in advanced/recurrent endometrial cancer (ESMO 2020)

Funding: Ability Pharmaceuticals SL. Clinical trial identification: EudraCT: 2016-001352-21.

over 4 years ago

Clinical • P2 data • Combination therapy

TRIB3 (Tribbles Pseudokinase 3)

carboplatin • paclitaxel • ibrilatazar (ABTL0812)